Any-cause and cause-specific hospitalisations ranged between 12% (any hospitalisation) and 72% (hospitalised for DM-related kidney complications) lower in the SGLT2 inhibitor-treated cohort compared to the DPP4 inhibitor-treated cohort. The gene discussed is SLC5A2; the disease is diabetes mellitus.